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H I G H L I G H T S
• Sleep disturbances are common findings in bipolar affective disorder.
• Na–K-ATPase is implicated in sleep regulation.
• Blocking of Na–K-ATPase by ouabain is an animal model of bipolar affective disorder.
• Intracerebroventriculary administered ouabain enhanced wakefulness.
• Homeostatic feed back mechanisms may be impaired in bipolar affective disorder.
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A B S T R A C T
Sleep disturbances are common findings in bipolar affective disorder (BD), and they may be related to the
pathophysiology of the disease. REM sleep deprivation, which has an antidepressant effect, increases Na–K-
ATPase (NKA) activity. NKA might be involved in the induction of rebound sleep. Decrements in NKA are
thought to be implicated in the pathophysiology of BD. A single intracerebroventricular (ICV) microinjection of
ouabain (OUA), an NKA inhibitor, results in long-lasting suppression of NKA activity. It has been proposed to be
used as a model of BD. To elucidate the role of NKA, we studied the effects of ICV administered OUA on the
sleep–wake activity of rats. Rats were ICV injected with saline on the baseline day and 2.5 μL 20 μM (n = 8) or
2 mM (n = 6) OUA on the subsequent OUA day. Saline was administered 1, 4, and 8 days after OUA injection.
Sleep–wake activity was recorded for 12 h or 24 h post-injection. OUA enhanced wakefulness, but there was only
little similarity between the changes in sleep and in BD after OUA treatment. These findings give only limited
support for the NKA hypothesis of BD. Not the decrease in NKA activity itself that may be the important factor in
the pathophysiology of BD, but rather the dysfunction of those regulatory processes that influence NKA.
1. Introduction
Patients suffering from mood disorders often complain of sleep
disturbances. Sleep abnormalities are similar in major depression and in
bipolar affective disorder (BD) (Riemann et al., 2002): sleep latency is
prolonged and sleep is fragmented. That is, there are many nocturnal
awakenings, and sleep terminates early in the morning. During non-
REM sleep, delta activity is decreased in the electroencephalogram
(EEG), and the first non-REM sleep period is shortened, leading to a
disinhibition and advanced occurrence of REM sleep, all representing
changes in the sleep architecture (Reynolds and Kupfer, 1987). Hy-
persomnia has also been reported in the depressive phase of BD
(Riemann et al., 2002). Furthermore, in mania, the amount of sleep is
reduced to a great extent (Soreca, 2014). Sleep can additionally influ-
ence mood. Manipulations of sleep–wake activity (total or partial sleep
deprivation, selective REM sleep deprivation, and phase advancement
of the sleep–wake cycle) are effective in relieving depression (Reynolds
and Kupfer, 1987; Riemann et al., 2002; Wirz-Justice and Van den
Hoofdakker, 1999). Therefore, these findings may indicate a relation-
ship between the underlying mechanisms of mood disorders and sleep
disturbances.
Sodium and potassium-activated adenosine triphosphatase (NKA)
dysfunction is thought to be implicated in the pathophysiology of BD,
and decreases in NKA activity may be related to the mechanisms un-
derlying both mania and bipolar depression (El-Mallakh, 1983; El
Mallakh and Wyatt, 1995). Decreases in NKA activity have been re-
ported in both mania and depression (Looney and El-Mallakh, 1997).
NKA activity is also suppressed in an animal model of depression
(Gamaro et al., 2003), and the levels of NKA suppressing endogenous
cardiac steroids are increased in an animal model of mania (Hodes
et al., 2016). In case of digitalis therapy, which suppresses NKA activity,
both mania and depression may occur as a side effect (Keller and
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Frishman, 2003). The suppression of NKA activity by in-
tracerebroventricular (ICV) administration of ouabain (OUA) has been
proposed to be used as an animal model of BD. The effect of ICV ad-
ministered OUA on motor activity depends on the way of recording. In
an automated activity monitor, ICV injection of 5 μL 1 mM OUA results
in a transient suppression of locomotor activity (Li et al., 1997).
However, when motor activity is measured by recording the open field
activity, the same treatment increases motor activity. When the open
field test is repeated 9 days after the OUA administration, the motor
activity is still high, indicating a long term action of OUA
(Ruktanonchai et al., 1998). Both OUA induced suppression and en-
hancement of motor activity can be prevented by lithium treatment (El-
Mallakh et al., 2003; Li et al., 1997).
REM sleep deprivation enhances neuronal NKA via the release of
noradrenaline and the activation of alpha-adrenergic receptors
(Gulyani and Mallick, 1995). Noradrenaline and NKA may also be im-
plicated in the changes of brain excitability following REM sleep de-
privation (Mallick and Singh, 2011). Since excitation of alpha1-adre-
nergic receptors during REM sleep deprivation may contribute to the
subsequent REM sleep rebound (Lelkes et al., 1994), it is possible that
the activation of NKA may also be involved in the generation of re-
bound sleep. Basal forebrain cholinergic neurons and the release of
adenosine are involved in the induction of rebound sleep (Porkka-
Heiskanen et al., 1997). Such an adenosine release may be linked to the
activation of NKA (Sims and Dale, 2014), which also supports the idea
that activation of NKA might be involved in the mechanism of rebound
sleep.
Thus, sleep disturbances are common findings in BD, and they may
be related to the pathophysiology of the disease. Besides, NKA might be
involved in both the regulation of sleep–wake activity and the patho-
physiology of BD. In order to clarify the role of NKA, the author studied
the effects of suppression of NKA activity by ICV administered OUA on
the sleep–wake activity of rats. In the present study, in addition to a
marked awakening effect, epileptiform waves appeared in the EEG in
response to a dose of 2.5 μL 2 mM OUA, equivalent to 5 μL 1 mM
proposed as an animal model of BD. Since a lower dose, without any
epileptogenic action, was thought to be a better model of BD, the effects
of such a low dose were also tested. The dose had to be reduced sub-
stantially in order not to induce any epileptiform wave in the EEG. After
testing several doses in pilot studies, 2.5 μL 20 μM OUA was proved not
to induce any epileptogenic action. In the present study, this low dose
only moderately enhanced wakefulness.
2. Methods
2.1. Animals
The experiments were carried out in male Sprague-Dawley rats
weighing 300–400 g at the time of the sleep experiments. The animals
were kept under conditions of controlled temperature (24+1 °C) and
lighting (lights on 8:30–20:30 h). Food and water were continuously
available. All efforts were made to minimize the number of animals
used and their suffering. Institutional guidelines for the care and use of
research animals were followed and approved by the respective in-
stitutional committees. The procedures used in this study are in ac-
cordance with the EU directive for animal experiments.
2.2. Surgery
The surgeries were performed under ketamine–xylazine anesthesia
(87 and 13 mg/kg, respectively). The animals were implanted with
stainless steel screw electrodes for EEG recordings over the cortex and
the cerebellum (EEG screw 1: 1 mm from the midline, on the sutura
coronarius; EEG screw 2: in the midline, 1.5–2 mm behind the lambda;
and ground screw: over the parietal cortex). An ICV guide cannula was
implanted into the left lateral cerebral ventricle stereotaxically
(0.80 mm posterior from bregma, 1.4 mm lateral from midline, and
4.0 mm ventral from the surface of the skull (Paxinos and Watson,
1998)). The guide cannula was fixed with dental acrylic (Duracryl) to
the skull. The location of the cannula was determined by the gravity
method (sudden drop in pressure) during implantation. The drinking
response to ICV injection of angiotensin was tested 3–4 days after
surgery. The rats responding to angiotensin were used in further stu-
dies. After the experiments, trypan blue was injected ICV, and the
ventricular system was checked for staining. The data refer to only the
rats (n = 14) in which the dye stained both the third and the fourth
ventricles and the cerebral aqueduct.
2.3. Recording
After the implantation operation, the rats lived in individual
Plexiglas cages in the experimental chamber. They were allowed 7–10
days to recover. The animals were connected to recording cables in
order to habituate them to the recording conditions. The recording
cables were attached to commutators. The motor activity was assessed
by means of recording potentials generated in electromagnetic trans-
ducers activated by movements of the cables (as performed previously,
cf., Lelkes et al., 1987). Cables from the commutators and electro-
magnetic transducers were connected to amplifiers. The digitized (128-
Hz sampling rate) signals of the EEG and motor activity were collected
by computers in an adjacent room. For scoring, the EEG and motor
activity signals were restored on the computer screen. EEG power
spectra were calculated by fast Fourier transformation (as performed
previously in this laboratory, cf. Obál et al., 1999). The states of vigi-
lance were determined for 8-s epochs by the usual criteria (used pre-
viously: Lelkes et al., 1987) as non-REM sleep (high-amplitude EEG
slow waves, lack of body movement, predominant EEG power in the
delta range); REM sleep (highly regular EEG theta activity with corre-
sponding high theta power, and general lack of body movements with
occasional twitches); and wakefulness (low-amplitude EEG, less regular
theta activity than during REM sleep, and frequent body movements).
2.4. Experimental protocol
After the surgery, the rats were allowed to recover and habituate to
the experimental conditions. Then, they received an ICV microinjection
of 2.5 μL SAL on the baseline day, the same volume of 20 μM (n = 8) or
2 mM (n = 6) OUA on the subsequent OUA day and SAL on the fol-
lowing post-OUA days 1, 4 and 8. The microinjections were given into
the lateral ventricle in dim light (lasting for 5–10 min) 5–15 min before
light onset. The sleep–wake activity was recorded for 12 (i.e., during
the light phase of each recording day; in case of the 2 mM OUA treated
rats) or 24 h (in case of the 20 μM OUA treated rats) post-injection.
2.5. Statistics
The percentage of time spent in each vigilance state and the slow
wave activity (SWA, EEG delta power, 0.5–4 Hz) during non-REM sleep
were calculated for consecutive 3-h time blocks. These 3-h values
among the various (baseline, OUA post-OUA) recording days were
compared by means of two-way analysis of variance (ANOVA) for re-
peated measures. The recording day effect (treatment effect, i.e. dif-
ferences among the baseline, OUA and post-OUA days) and the time of
day effect (variations in 3-h values across the day) were the two factors
included in the ANOVA. In general, the F statistics are reported only for
the recording day (treatment) effect and for the interactions between
the recording day and the time of day factors when the differences were
proved to be statistically significant. The Bonferroni test was used for
post hoc comparisons. The numbers of wake, non-REM and REM sleep
epochs for the 12-h recording periods and REM sleep latencies were
calculated. Since the sleep–wake activity of animals is polyphasic, and
not each non-REM sleep episode is followed by REM sleep, it is difficult
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to measure REM sleep latency in rats. REM sleep latency was defined as
the delay between the onset of the 1st at least 120-s long epoch of sleep
and the 1st at least 40-s long REM sleep epoch of the light phase. (In an
earlier study, when sleep-wake activity was scored in 40-sec epochs, we
defined REM sleep latency as the time between the onset of light and
the occurrence of the 1st episode of REM sleep; Obál et al., 1985. In the
present study, this criterion was modified, REM sleep latency was de-
fined as the time between sleep onset and the occurrence of the first at
least 40-s long episode of REM sleep. Sleep onset was defined as the as
the onset of the 1st at least 120-s long sleep epoch, as done by Cui et al.,
2007) These values among the various (baseline, OUA post-OUA) re-
cording days were compared by means of one-way ANOVA for repeated
measures. The Bonferroni test was used for post hoc comparisons. Va-
lues of p < 0.05 were considered to be significant.
3. Results
The 2.5 μL 2 mM dose of OUA had a robust awakening effect, be-
sides, epileptiform waves appeared in the EEG following administration
of the drug. In order to avoid the induction of epileptiform waves the
dose had to be substantially reduced. In a dose of 2.5 μL 20 μM, OUA
had only a moderate awakening action without inducing any epilepti-
form waves.
3.1. Effects of 2.5 μL 2 mM OUA
Epileptiform waves (spikes and slow waves) appeared in the EEG in
10–15 min after the administration of 2.5 μL 2 mM OUA, and they often
reappeared during the 12-h recording on the day of OUA administration
(41 ± 11.6% of the 8-s intervals contained more or less epileptiform
waves, usually only in a just noticeable amount, but sometimes these
waveforms dominated the EEG; Fig. 1). No behavioral sign of epilepsy
was noted, but it has to be mentioned that the behavior of the animals
was not observed systematically. (In the lack of cameras in the re-
cording chambers, such an observation was not possible without dis-
turbing the sleep-wake activity of the rats.)
A robust arousing action was noted after administration of 2.5 μL
2 mM OUA (Fig. 2). The percentage of time spent in wakefulness dis-
played a diurnal (time of day) variation (ANOVA, F(3,15) = 5.492,
p = 0.0095). The amount (ANOVA, F(4,20) = 8.929, p = 0.0003) and
the daily distribution (ANOVA, recording day x time of day interaction,
F(12,60) = 6.593, p < 0.0001) of wakefulness varied among the
different (baseline, OUA, post-OUA 1, 4 and 8) recording days. More
time was spent in wakefulness during the day of OUA administration
then on the baseline day (Bonferroni test, p = 0.0055), wakefulness
was enhanced in the initial post-administration 3-h period of the OUA
day (Bonferroni test, p = 0.0064). The percentage of time spent in non-
REM sleep had a diurnal (time of day) variation (ANOVA, F
(3,15) = 9.238, p = 0.0011). The amount (ANOVA, F(4,20) = 6.766,
p = 0.0013) and the daily distribution (ANOVA, recording day x time
of day interaction, F(12,60) = 7.934, p < 0.0001) of non-REM sleep
varied among the different (baseline, OUA, post-OUA 1, 4 and 8) re-
cording days. Non-REM sleep was suppressed in the initial post-ad-
ministration 3-h period of the OUA day (Bonferroni test, p = 0.0059).
The amount of REM sleep displayed a diurnal (time of day) variation
(ANOVA, F(3,15) = 9.369, p = 0.0009). The percentage of time spent
in REM sleep (ANOVA, F(4,20) = 8.339, p = 0.0004) and the daily
distribution of REM sleep (ANOVA, recording day x time of day inter-
action, F(12,60) = 2.342, p = 0.0154) varied among the different
recording days. Less time was spent in REM sleep during the OUA
(Bonferroni test, p = 0.0154) and the 1st post-OUA (Bonferroni test,
p = 0.0203) days then on the baseline day, REM sleep was suppressed
in the 2nd (Bonferroni test, p = 0.0339) and 3rd (Bonferroni test,
p = 0.0382) post-administration 3-h period of the day of OUA ad-
ministration.
The number of wake (ANOVA, F(4,20) = 13.027, p < 0.0001),
non-REM sleep (ANOVA, F(4,20) = 11.990, p < 0.0001), and REM
sleep (ANOVA, F(4,20) = 6.567, p = 0.0015) epochs varied among the
different (baseline, OUA, post-OUA 1, 4 and 8) recording days. The
number of wake (Bonferroni test, p = 0.0055), non-REM sleep
(Bonferroni test, p = 0.0085) and REM sleep (Bonferroni test,
p = 0.0447) epochs were decreased on the day of OUA administration.
(On the OUA day sleep-wake activity was dominated by long W
epochs.) REM sleep latency also varied among the different recording
days (ANOVA, F(4,20) = 13.628, p < 0.0009). REM sleep latency was
elongated on the day of OUA administration (Bonferroni test,
p = 0.0010), Table 1).
3.2. Effects of 2.5 μL 20 μM OUA
No epileptiform wave was induced by 2.5 μL 20 μM OUA.
This, low dose of OUA had a weak arousing action on the day of
administration (Fig. 3). The amount of wakefulness displayed a diurnal
(time of day) variation (ANOVA, F(7,49) = 48.443, p < 0.0001). The
daily distribution of wakefulness varied among the different (baseline,
OUA, post-OUA 1, 4 and 8) recording days (ANOVA, recording day x
time of day interaction, F(28,196) = 2.274, p < 0.0006). Wakefulness
was enhanced during the 12-h light period of the OUA day (Bonferroni
test, p = 0.0384). No significant change was noted for any of the in-
dividual 3-h periods (Bonferroni test). This arousal effect was followed
by an opposite reaction, wakefulness tended to decrease during the
dark period. The amount of non-REM sleep had a diurnal (time of day)
variation (ANOVA, F(7,49) = 70.556, p < 0.0001). The daily dis-
tribution of non-REM sleep also varied among the different recording
days (ANOVA, recording day x time of day interaction, F
(28,196) = 1.866, p < 0.0077). The 12-h or 3-h values did not differ
significantly from those of the corresponding baseline period (Bonfer-
roni test). On the day of OUA administration, tendencies were noted in
non-REM sleep to be decreased and increased during the light and dark
12-h periods, respectively. The amount of REM sleep displayed a
diurnal (time of day) variation (ANOVA, F(7,49) = 7.521,
p < 0.0001). The daily distribution of REM sleep varied among the
different recording days (ANOVA, recording day x time of day inter-
action, F(28,196) = 2.413, p < 0.0002). REM sleep was suppressed in
the 12-h light period of the OUA day (Bonferroni test, p = 0.0216). No
significant change was noted for any of the individual 3-h periods
(Bonferroni test). Following the suppression in the light period, a ten-
dency to a compensatory increase was noted during the dark period.
This low dose of OUA did not elicit any significant change in the
other sleep parameters: SWA during NREMS; the number of wake, non-
REM and REM sleep epochs; REM sleep latency (ANOVA), only ten-
dencies to increase the numbers of wake and non-NREM sleep and to
decrease the number of REM sleep epoch were noted on the OUA day
(Table 2).
Fig. 1. Epileptiform EEG waves induced by 2.5 μL 2 mM OUA microinjection.
A: non-REM sleep to wakefulness transition on the baseline day (control EEG
recording); B: Epileptiform waves in the EEG on the OUA day.
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Fig. 2. Effects of 2.5 μL 2 mM OUA microinjection on sleep. The ICV microinjections were administered 5–15 min prior the onset of recordings. The top curves
display the patterns of wakefulness (W), non-REM sleep (NREMS), and REM sleep (REMS) as the percentage of recording time on the baseline day (SAL), OUA day
(OUA) and post-OUA days 1, 4, and 8 (SAL). The histograms represent the differences from baseline day values. Data are computed for consecutive 3-h bins (mean
values ± SE). The horizontal lines above (W) or below (REMS) the histograms denote significant differences between the given day and the baseline day (Bonferroni
test, p < 0.05), the asterisk denotes significant differences of the 3-h values from baseline (Bonferroni test, p < 0.05).
Table 1
Effects of Effects of 2.5 μl 2 mM OUA microinjection: the numbers of W, NREMS and REMS epochs and the REM sleep latencies on the baseline day (SAL), OUA day
(OUA) and postOUA days 1, 4 and 8 (SAL), mean values ± SE.
The number of W epochs The number of NREMS epochs The number of REMS epochs REM sleep latency (min)
Baseline day 190.2 ± 11.2 194.0 ± 12.0 33.0 ± 7.3 91.7 ± 27,9
OUA day 74.0 ± 20.1* 78.5 ± 22.0* 1.8 ± 1.6* 660.3 ± 47.5*
PostOUA day 1 146.7 ± 18.7 166.0 ± 14.0 15.5 ± 7.9 358.1 ± 103.5
PostOUA day 4 173.5 ± 19.0 174.8 ± 18.6 28.7 ± 5.5 154.8 ± 71.8
PostOUA day 8 178.3 ± 12.5 178.8 ± 12.5 15.7 ± 4.6 159.6 ± 36.0
*p < 0.5 (Bonferroni test).
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4. Discussion
The main finding of the present study was that suppression of NKA
activity by both doses of OUA enhanced wakefulness. ICV administra-
tion of 5 μL 1 mM OUA exerts a long lasting influence on open field
activity, which is still enhanced when the test is repeated several days
after the administration of the drug (Ruktanonchai et al., 1998). In the
present study, no similar long lasting effect on sleep was found. How-
ever, the open field test and sleep recording are performed in different
conditions. In case of an open field test, the animal is placed into an
Fig. 3. Effects of 2.5 μL 20 μM OUA microinjection on the SWA and sleep. The ICV microinjections were administered 5–15 min prior to the onset of recordings. The
top curves display the patterns of SWA during non-REM sleep (NREMS) as the percentage of baseline day 24-h mean value, wakefulness (W), non-REM sleep
(NREMS), and REM sleep (REMS) as the percentage of recording time on the baseline day (SAL), OUA day (OUA), and post-OUA days 1, 4, and 8 (SAL). The
histograms represent the differences from the baseline day values. The data are computed for consecutive 3-h bins (mean values ± SE). The light and dark horizontal
bars on the X axis indicate light and dark phases, respectively. The horizontal lines above (W) or below (REMS) the histograms denote significant differences between
the light 12-h values of OUA day and the baseline (Bonferroni test, p < 0.05).
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open field equipment, i.e., into a new environment, whereas sleep re-
cording is performed in the home cage. Our findings are in line with
those of Kirshenbaum et al. (2011), who have reported enhancement of
wake and suppressions of non-REM and REM sleep in genetically
modified mice with decreased NKA activity. The enhancement of wa-
kefulness in the present study may be related to an increase in neuronal
excitability and activity, which is caused by a moderate decrease in
NKA activity. The function of NKA is necessary for the excitability, but a
moderate decrease in NKA activity can increase the excitability and the
release of neurotransmitters (El Mallakh and Wyatt, 1995; McCarren
and Alger, 1987). The appearance of epileptiform waves in the EEG
following the administration of the high (2.5 μL 2 mM) dose of OUA is
probably an indication of the increased excitability. Seizures have al-
ready been reported in response to OUA administration by Davidson
et al. (1978). Interestingly, however, the suppression of endogenous
OUA-like compounds by the administration of anti-OUA antibodies
(such a treatment should decrease neuronal activity by increasing NKA
activity) into the locus coeruleus, a nucleus containing noradrenergic
REM-off neurons, decreases the amount of REM sleep (Jaiswal et al.,
2010).
Additionally, sleep can influence NKA activity. REM sleep depriva-
tion enhances neuronal NKA via noradrenaline and activation of
alpha1-adrenergic receptors (Baskey et al., 2009). Phospholipase C and
changes of intracellular calcium concentration are involved in the
mediation of the noradrenaline induced enhancement of NKA (Amar
and Mallick, 2018). By contributing to the maintenance of neuronal
homeostasis, NKA might be involved in the homeostatic regulation of
the sleep–wake activity. During a prolonged wake period, neuronal
activity of the wake-promoting neurons rises. In case of neuronal acti-
vation, the intracellular accumulation of sodium, due to the influx of
the ion during action potentials, results in an enhancement of NKA,
which in turn decreases the excitability (El-Mallakh, 1983; Johar et al.,
2014; Sims and Dale, 2014). The decrease in excitability may result in a
drop of activity of the wake-promoting neurons leading to a sleep re-
bound following a long wake period. Wake-promoting, cholinergic
neurons in the basal forebrain, which are also involved in the mediation
of the arousing action of noradrenaline via alpha1-adrenergic receptors
(Lelkes et al., 2013), have an important role in the induction of rebound
sleep (Porkka-Heiskanen et al., 1997). Wake-associated increase in the
activity of these neurons results in the release of adenosine, which in-
hibits the activity of these cholinergic cells and is involved in the in-
duction of subsequent rebound sleep and the enhancement of SWA
(Porkka-Heiskanen et al., 1997). Activity-dependent adenosine release
may be linked to the activation of NKA (Sims and Dale, 2014). In case of
neuronal activation, the enhanced NKA consumes ATP leading to a
release of adenosine. Thus, blocking the NKA suppresses sleep, and
sleep deprivation results in an enhancement of NKA, which may be
involved in the induction of the subsequent sleep rebound. All these
lines of evidence support the opinion that NKA may be involved in the
regulation of the sleep–wake activity.
In addition to an enhancement of wakefulness, epileptiform waves
appeared in the EEG in response to the high (2.5 μL 2 mM) dose of OUA.
Though major depression is often accompanied by epilepsy, BD is rarely
seen in epileptic patients (Schmitz, 2005). The lower (2.5 μL 20 μM)
dose, without any epileptogenic action, appears to be a better model of
BD than the high one. Since the administration of OUA has been pro-
posed as an animal model of BD, changes of sleep–wake activity in-
duced by this treatment should mimic those in mood disorders. In fact,
wakefulness was enhanced by both doses of OUA in the present study.
After an enhancement of wakefulness during the light 12-h period by
the low dose (OUA was administered at light onset) tendencies to in-
crease in sleep were noted in the following dark period, i.e., the loss of
sleep in the light (rest) phase of the day was compensated during the
dark (active) phase. Naps and circadian disturbances have been ob-
served in BD (Riemann et al., 2002; Soreca, 2014). While the time spent
in non-REM sleep tended to be reduced, a tendency to an increase in the
number of non-REM sleep epochs was noted in response to the low dose
of OUA, which might be a sign of fragmented NREM sleep. Fragmented
sleep has been reported in mood disorders (Reynolds and Kupfer,
1987). Nonetheless, REM sleep latency was not found to be shortened in
the present study. Shortening of REM sleep latency is also a char-
acteristic feature of sleep disturbances in BD (Riemann et al., 2002).
However, it is noteworthy that measuring REM sleep latency in animals
is difficult, and it is not fully proved that the REM sleep latency mea-
sured in the present study is a real equivalent of the human REM sleep
latency. In contrast to the present findings, a shortened REM sleep la-
tency has been reported in genetically modified mice with decreased
NKA activity (Kirshenbaum et al., 2011). In BD, the first non-NREM
sleep period is shortened leading to a disinhibition and advanced oc-
currence of REM sleep (Riemann et al., 2002). No similar disinhibition
and advanced occurrence of REM sleep or changes in sleep architecture
was noted in response to OUA in the present study. Though sleep was
suppressed by OUA, changes of sleep in BD were not really mimicked
following the treatment with the drug. Whereas sleep in genetically
modified mice is more similar to that in BD.
The present study was performed on rats. Though rats are nocturnal
animals, otherwise their sleep is similar to that of diurnal ones. Despite
of the diversity of the sleep characteristics of mammals there is no in-
dication of fundamental differences in sleep among the various, diurnal
and nocturnal, species (Tobler, 1995). Nocturnal animals are often used
in sleep research, pharmacological sleep studies are often performed on
rats. If it is taken to consideration that in rats the night and day are the
active and rest phases, respectively, conclusions can be drawn even
regarding the human sleep, though only with caution. Besides,
homeostatic regulation of sleep is relatively independent of the circa-
dian rhythm (Tobler, 1995). NKA might be involved in the homeostatic
regulation of sleep. The effects of OUA on sleep architecture were also
examined in the present study. There are notable similarities between
the sleep architecture of rats and humans (Roncagliolo and Vivaldi,
1991).
The present findings give only limited support for the NKA hy-
pothesis of BD. Though NKA has been found to be suppressed in BD in
most of the studies, at least in one paper, increases have also been re-
ported (Sengupta et al., 1980). There may be a link between NKA and
the underlying mechanisms of BD; however, it is possible that not ne-
cessarily the decrease in NKA activity itself is the important factor but
the dysfunction of the regulatory mechanisms influencing NKA. These
regulatory functions may be impaired in BD resulting in a decrease of
NKA activity or a lack of compensatory increase. In fact, the lack of
similar adaptive responses has been reported in BD. When lymphocytes
Table 2
Effects of 2.5 μl 20 μM OUA microinjection: the numbers of W, NREMS and REMS epochs and the REM sleep latencies on the baseline day (SAL), OUA day (OUA) and
postOUA days 1, 4 and 8 (SAL), mean values ± SE.
The number of W epochs The number of NREMS epochs The number of REMS epochs REM sleep latency (min)
Baseline day 294.3 ± 15.4 307.8 ± 13.7 80.3 ± 7.2 35.8 ± 7.1
OUA day 342.0 ± 16.3 354.4 ± 16.9 73.8 ± 9.5 37.2 ± 15.7
PostOUA day 1 294.6 ± 16.3 304.6 ± 15.6 69.8 ± 6.7 49.4 ± 8.4
PostOUA day 4 288.8 ± 13.8 302.0 ± 13.3 77.6 ± 8.0 35.2 ± 6.6
PostOUA day 8 297.5 ± 14.7 310.8 ± 12.7 82.8 ± 11.2 46.9 ± 10.1
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of healthy subjects are incubated with lithium or ethacrynate, there is
an increase in the number of NKA molecules. This response is missing in
BD (Wood et al., 1991). Furthermore, the level of SP4 protein, a key
enzyme in the activity dependent enhancement of NKA, is reduced in
BD (Johar et al., 2014; Pinacho et al., 2011). These negative feedback
processes influencing NKA are important for the maintenance of the
homeostasis of neurons, and they are also involved in the homeostatic
sleep regulatory mechanisms. The decrease in slow wave sleep in BD
(Riemann et al., 2002) may mirror the dysfunction of these processes.
This dysfunction may be a link between the underlying mechanisms of
mood disorders and sleep disturbances. Since malfunctioning of the
negative feedback regulation can also result in an oscillation of the
regulated parameter, it may also be an explanation for the oscillation in
mood in BD.
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